• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Eli Lilly

Eli Lilly

Eli Lilly and Co LLY 2 Star

Last Price$83.49Day Change (%)-0.35%
Open Price$84.50Day Change ($)-0.29
Day Range83.38–84.5752-Week Range60.14–87.24

As of Tue 6/30/2015 6:58:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Eli Lilly Wins Alimta Patent Case in U.K.

    Eli Lilly Wins Alimta Patent Case in U.K.

  2. Eli Lilly Wins Alimta Patent Case in U.K.

    Eli Lilly Wins Alimta Patent Case in U.K.

  3. Anacor Pharmaceuticals Announces Amendment to KERYDIN Commercialization Agreement

    Anacor Pharmaceuticals Announces Amendment to KERYDIN Commercialization Agreement

  4. Eli Lilly's stock extends recent surge, but Leerink analyst expresses concern

    Eli Lilly's stock extends recent surge, but Leerink analyst expresses concern

  5. UPDATE: Micron tanks in after hours as profit slumps; Nike up on earnings

    UPDATE: Micron tanks in after hours as profit slumps; Nike up on earnings

  6. Charting a sluggish, but bullish, summer trend

    Charting a sluggish, but bullish, summer trend

  7. Prize4Life, Sage Bionetworks and DREAM Launch an Open Science Challenge to Find Clues to Understanding Heterogeneity in Patients with Amyotrophic Lateral Sclerosis (ALS)

    Prize4Life, Sage Bionetworks and DREAM Launch an Open Science Challenge to Find Clues to Understanding Heterogeneity in Patients with Amyotrophic Lateral Sclerosis (ALS)

  8. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

    Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.

  9. CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology

    CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology

  10. UPDATE: 5 ways to profit from sex (without having it)

    UPDATE: 5 ways to profit from sex (without having it)

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.